CD3+免疫细胞内型与PsA疾病表型及先进治疗应答相关
该研究用质谱流式分析34例PsA患者(40个治疗周期)启动靶向治疗时的CD3+免疫细胞群,层次聚类识别出3种免疫内型,分别与超声肌肉骨骼炎症、附着点骨形成及治疗应答相关,蛋白组学提示记忆CD4+内型WNT等通路失调。
要点
- 识别出3种CD3+免疫内型:记忆CD4+T细胞型、非经典T细胞型、终末效应/Th1细胞型。
- 记忆CD4+T细胞内型与更高超声肌肉骨骼炎症和附着点骨形成及较差治疗应答相关。
- 免疫内型在治疗后3个月保持相对稳定,滑膜组织中记忆和效应表型CD4+细胞丰富。
核心结论
- 循环免疫细胞谱异质性与PsA临床特征和治疗应答相关。
- 免疫细胞表型分析有潜力改善PsA预后并辅助个体化治疗策略。
研究设计与样本
- 研究纳入34例启动靶向治疗的PsA患者共40个治疗周期,用质谱流式分析CD3+免疫细胞群。
- 用层次聚类识别免疫细胞内型,用广义估计方程模型评估其与临床特征和治疗应答的关联。
- 用基于适配体的蛋白组学比较不同聚类间的差异蛋白并进行通路分析。
- 对PsA患者滑膜组织样本进行成像质谱流式分析以表征T细胞亚群。
主要发现
- 识别出3个免疫聚类(C):C1为「记忆CD4+T细胞内型」,与更高超声肌肉骨骼炎症和附着点骨形成及较差治疗应答相关。
- C2为「非经典T细胞内型」,表现出最低水平的肌肉骨骼炎症。
- C3为「终末效应/Th1细胞内型」,与更高超声附着点炎症相关。
- 免疫内型在治疗后3个月保持相对稳定。
- 记忆CD4+T细胞内型以免疫相关生物学通路失调为特征,包括若干细胞内信号通路,最显著为WNT信号通路;PsA患者滑膜组织样本中记忆和效应表型CD4+细胞丰富。
关键数值与推荐
- 共分析34例患者的40个治疗周期血液样本,识别出3个免疫聚类(C1、C2、C3)。
临床怎么用
- 循环CD3+免疫细胞表型分析可能有助于改善PsA预后判断,并可能为个体化治疗策略提供信息。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to identify circulating cellular immune cell endotypes in psoriatic arthritis (PsA), assess their association with treatment response, and explore key biological pathways linked to these immune profiles. METHODS: Using mass cytometry, we analysed CD3+ immune cell populations in patients with PsA initiating targeted therapies. Hierarchical clustering identified immune cell endotypes, and their associations with clinical features and treatment response were assessed using generalised estimating equation models. Proteomic profiling via an aptamer-based assay compared differentially expressed proteins across clusters, followed by pathway analysis. Imaging mass cytometry analysis was performed to characterise T cell subsets in synovial tissue samples. RESULTS: We analysed blood samples from 40 treatment periods involving 34 patients and identified 3 immune clusters (C); C1: 'memory CD4+ T cell endotype' - associated with higher sonographic musculoskeletal inflammation and peri-articular bone formation, and poorer response to therapy; C2: 'Nonclassical T cell endotype'-exhibited lowest levels of musculoskeletal inflammation; and C3: 'Terminal effector/Th1 cell endotype'-linked to higher sonographic peri-articular inflammation. The immune endotypes remained relatively stable 3 months posttreatment. The 'memory CD4+ T cell endotype' was characterised by deregulation of immune-related biological pathways, including several intracellular signalling pathways, the most notable being WNT signalling. CD4+ cells with memory and effector phenotypes were abundant in the synovial tissue sample from patients with PsA. CONCLUSIONS: Heterogeneity in circulating immune cell profiles is associated with PsA clinical features and therapeutic response. The results underscore the potential of immune cell phenotyping to improve prognosis in PsA, which could inform personalised treatment strategies.
引用
- Eder L, Dang S, Caucheteux SM, et al. CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study. Ann Rheum Dis. 2025. PMID: 41206244. doi:10.1016/j.ard.2025.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。